Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SANDIMMUNE vs LUPKYNIS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cyclosporine is a calcineurin inhibitor. It binds to cyclophilin, forming a complex that inhibits calcineurin, thereby blocking the dephosphorylation and nuclear translocation of NF-AT, reducing T-cell activation and cytokine production.
Calcineurin inhibitor immunosuppressant that binds to cyclophilin A, inhibiting calcineurin activity, which prevents dephosphorylation and activation of nuclear factor of activated T-cells (NFAT), thereby reducing cytokine production and T-cell activation.
Prophylaxis of organ rejection in kidney, liver, and heart transplants,Treatment of chronic allograft rejection in kidney, liver, and heart transplants,Severe active rheumatoid arthritis (FDA-approved),Psoriasis (FDA-approved),Off-label: atopic dermatitis, nephrotic syndrome, severe ulcerative colitis, aplastic anemia
Treatment of lupus nephritis in combination with a background immunosuppressive therapy
Initial oral dose: 10-15 mg/kg/day divided q12h, then taper to 5-10 mg/kg/day. IV dose: 5-6 mg/kg/day continuous infusion or divided q12h.
23.7 mg orally twice daily with food.
Terminal elimination half-life is approximately 8.4 hours (range 6–24 hours) in adults; prolonged in patients with hepatic impairment.
Terminal elimination half-life approximately 30 hours; supports once-daily dosing; steady-state reached by day 4.
Primarily hepatic via CYP3A4; undergoes extensive first-pass metabolism. Metabolites are excreted primarily in bile and feces.
Primarily metabolized by CYP3A4; minor contribution from CYP3A5.
Primarily biliary/fecal (94% of metabolites); renal elimination is minimal (<6% as unchanged drug and metabolites).
Primarily hepatic metabolism; <1% excreted unchanged in urine; approximately 66% of total radioactivity recovered in feces (mainly metabolites) and 22% in urine (mainly metabolites).
90–98% bound, primarily to lipoproteins and albumin.
Greater than 99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
3–5 L/kg in adults; high distribution indicates extensive tissue binding, including to erythrocytes and lymphocytes.
Apparent Vd/F ~24 L (approximately 0.34 L/kg assuming 70 kg); indicates distribution into tissues.
Oral: 30% (range 10–60%) due to extensive first-pass metabolism; IV: 100%; ophthalmic: not quantified, minimal systemic absorption.
Oral bioavailability approximately 35% (range 20–50%) under fasting conditions; high-fat meal reduces Cmax and AUC by about 50%.
For Cr Cl < 30 m L/min: reduce dose by 25-50%. Monitor serum creatinine closely. Avoid in severe renal impairment unless benefit outweighs risk.
No dose adjustment required for GFR ≥30 m L/min. Avoid use in severe renal impairment (GFR <30 m L/min) due to lack of data.
Child-Pugh A: no adjustment. Child-Pugh B or C: reduce dose by 25-50%. Monitor cyclosporine levels and hepatic function.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose to 15.8 mg orally twice daily. Child-Pugh Class C: Not recommended.
Children: 10-15 mg/kg/day oral divided q12h; IV: 5-6 mg/kg/day. Adjust based on trough levels (target 100-400 ng/m L).
Safety and efficacy not established in pediatric patients; no approved dose.
Start at low end of dosing range due to reduced renal and hepatic function. Monitor renal function and cyclosporine levels, as elderly are more susceptible to nephrotoxicity.
No specific dose adjustment required; monitor renal function due to age-related decline.
Increased susceptibility to infection and possible development of lymphoma and other malignancies. Only physicians experienced in immunosuppressive therapy and management of organ transplant patients should prescribe Sandimmune.
Increased risk of infection and lymphoma; increased risk of nephrotoxicity and hypertension; increased risk of neurotoxicity.
Nephrotoxicity: Monitor renal function closely; dose-dependent and may progress to chronic nephropathy.,Hepatotoxicity: Elevations in liver enzymes and bilirubin.,Hypertension: Common; may require antihypertensive therapy.,Neurotoxicity: Tremor, convulsions, headache, and other neurological effects.,Hyperkalemia: Risk increases with concurrent use of potassium-sparing diuretics or ACE inhibitors.,Hypomagnesemia: Monitor magnesium levels.,Vaccinations: Live vaccines may be less effective and should be avoided.,Carcinogenesis: Increased risk of skin cancer and lymphoproliferative disorders.
Nephrotoxicity and hypertension require regular monitoring. Neurotoxicity including posterior reversible encephalopathy syndrome (PRES). Increased susceptibility to infections including opportunistic infections. Malignancies including lymphoma. Monitor for Epstein-Barr virus serology. Use with caution with CYP3A4 inhibitors and inducers. Avoid live vaccines.
Hypersensitivity to cyclosporine or any component of the formulation,Concurrent use with PUVA or UVB therapy in psoriasis patients (increased risk of skin cancer),Uncontrolled hypertension or malignancy (relative for non-transplant indications)
Concurrent use with chronic immunosuppressive therapies other than mycophenolate mofetil (MMF) or mycophenolic acid (MPA). Known hypersensitivity to voclosporin or any component of the formulation.
Avoid grapefruit and grapefruit juice. High-fat meals may reduce absorption; administer consistently with or without food. Do not take with potassium-rich foods or salt substitutes without monitoring.
Avoid grapefruit and grapefruit juice as they increase voclosporin exposure. No other specific food interactions are known.
Cyclosporine is not a major human teratogen. First trimester exposure is not associated with an increased risk of major birth defects, but may increase the risk of preterm birth (28-33 weeks) and low birth weight. Second and third trimester use is associated with increased risk of gestational hypertension, preeclampsia, and fetal growth restriction. Prematurity and transient neonatal immunosuppression have been reported.
LUPKYNIS (voclosporin) is a calcineurin inhibitor. Based on animal studies, there is a risk of fetal harm in all trimesters. In rats and rabbits, voclosporin administration during organogenesis resulted in increased embryofetal mortality and reduced fetal weight at maternally toxic doses. There are no adequate human studies. Avoid use during pregnancy unless potential benefit outweighs risk.
Cyclosporine is excreted into human breast milk. The milk-to-plasma ratio (M/P) ranges from 0.17 to 1.4, with an average of approximately 0.5. The relative infant dose is estimated to be less than 2% of the maternal weight-adjusted dose. Breastfeeding is generally considered acceptable if maternal levels are maintained within therapeutic range and infant is monitored for potential adverse effects (e.g., immunosuppression).
It is unknown if voclosporin is excreted in human milk. In animal studies, voclosporin and its metabolites were detected in milk of lactating rats. No M/P ratio available for humans. Due to potential for serious adverse reactions in nursing infants, advise women not to breastfeed during treatment and for 4 weeks after last dose.
Pregnancy induces increased volume of distribution and enhanced clearance of cyclosporine, leading to decreased trough levels. Dose adjustments may be required, especially in the second and third trimesters. Increase dose as needed to maintain therapeutic trough concentrations (typically 100-400 ng/m L, depending on indication). Postpartum, dose should be reduced back to prepregnancy levels due to return of normal clearance.
No specific dose adjustments are established for pregnancy. However, pregnancy can increase voclosporin clearance due to expanded plasma volume and enhanced metabolism. Consider therapeutic drug monitoring if available, and adjust dose to maintain therapeutic trough levels (target 30-60 ng/m L) as needed.
Monitor trough levels 12 hours post-dose; target varies by transplant organ (e.g., 200-400 ng/m L for kidney, 250-800 ng/m L for liver early post-transplant). Adjust for hepatic dysfunction; cyclosporine is extensively metabolized by CYP3A4. Avoid live vaccines. Use with caution in renal impairment; dose reduction may be needed. Drug interactions: avoid with potassium-sparing diuretics due to hyperkalemia risk; monitor for gingival hyperplasia and hypertension.
Monitor for hematuria, proteinuria, and e GFR during treatment. Lupkynis (voclosporin) is a calcineurin inhibitor; do not co-administer with other CNIs or strong CYP3A4 inhibitors. Reduce dose in patients with e GFR <45 m L/min per 1.73 m². Concomitant use with mycophenolate mofetil and corticosteroids is standard. Check blood pressure and serum potassium regularly. Live vaccines contraindicated.
Take at the same time every day with a full glass of water, consistently with or without food.,Do not consume grapefruit or grapefruit juice; it can increase cyclosporine levels.,Report signs of infection (fever, sore throat), tremors, or changes in urine output.,Avoid live vaccines (e.g., MMR, nasal flu spray) and contact with recently vaccinated individuals.,Use sunscreen as cyclosporine may increase sensitivity to sunlight.,Do not change brand or dosage form without consulting prescriber.
Take exactly as prescribed; do not stop or change dose without consulting your doctor.,You will need regular blood and urine tests to monitor kidney function and drug levels.,Report any signs of infection (fever, sore throat), high blood pressure (severe headache, vision changes), or changes in urine output/color.,Avoid grapefruit and grapefruit juice during treatment.,Do not receive live vaccines while taking this medication.,Use effective contraception during treatment and for 12 weeks after last dose if of childbearing potential.,Tell your doctor about all medications, including over-the-counter drugs and supplements.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SANDIMMUNE vs LUPKYNIS, answered by our medical review team.
SANDIMMUNE is a Calcineurin Inhibitor that works by Cyclosporine is a calcineurin inhibitor. It binds to cyclophilin, forming a complex that inhibits calcineurin, thereby blocking the dephosphorylation and nuclear translocation of NF-AT, reducing T-cell activation and cytokine production.. LUPKYNIS is a Calcineurin Inhibitor Immunosuppressant that works by Calcineurin inhibitor immunosuppressant that binds to cyclophilin A, inhibiting calcineurin activity, which prevents dephosphorylation and activation of nuclear factor of activated T-cells (NFAT), thereby reducing cytokine production and T-cell activation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SANDIMMUNE and LUPKYNIS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SANDIMMUNE is: Initial oral dose: 10-15 mg/kg/day divided q12h, then taper to 5-10 mg/kg/day. IV dose: 5-6 mg/kg/day continuous infusion or divided q12h.. The standard adult dose of LUPKYNIS is: 23.7 mg orally twice daily with food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SANDIMMUNE and LUPKYNIS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SANDIMMUNE is classified as Category C. Cyclosporine is not a major human teratogen. First trimester exposure is not associated with an increased risk of major birth defects, but may increase the risk of preterm birth (2. LUPKYNIS is classified as Category C. LUPKYNIS (voclosporin) is a calcineurin inhibitor. Based on animal studies, there is a risk of fetal harm in all trimesters. In rats and rabbits, voclosporin administration during . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.